Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer

Meng Wu,1,2 Ying Wang,3 Yiru Wang,2 Mingbo Zhang,2 Yukun Luo,2 Jie Tang,2 Zhigang Wang,4 Dong Wang,5 Lan Hao,4 Zhibiao Wang6 1School of Medicine, Nankai University, Tianjin, 2Department of Ultrasound, Chinese PLA General Hospital, Beijing, 3Wuhan Textile University, Wuhan, 4Chongqing Key Laboratory...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wu M, Wang Y, Wang YR, Zhang MB, Luo YK, Tang J, Wang ZG, Wang D, Hao L, Wang ZB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	nanobubbles ultrasound imaging paclitaxel cancer therapy aptamer prostate-specific membrane antigen Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4434a01d73bb415e941cf48af19d7af0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4434a01d73bb415e941cf48af19d7af0
record_format	dspace
spelling	oai:doaj.org-article:4434a01d73bb415e941cf48af19d7af02021-12-02T04:09:37ZPaclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer1178-2013https://doaj.org/article/4434a01d73bb415e941cf48af19d7af02017-07-01T00:00:00Zhttps://www.dovepress.com/paclitaxel-loaded-and-a10-32-aptamer-targeted-polylactide-co-glycolic--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Meng Wu,1,2 Ying Wang,3 Yiru Wang,2 Mingbo Zhang,2 Yukun Luo,2 Jie Tang,2 Zhigang Wang,4 Dong Wang,5 Lan Hao,4 Zhibiao Wang6 1School of Medicine, Nankai University, Tianjin, 2Department of Ultrasound, Chinese PLA General Hospital, Beijing, 3Wuhan Textile University, Wuhan, 4Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, 5Department of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, 6College of Biomedical Engineering, Chongqing Medical University, Chongqing, People’s Republic of China Abstract: In the current study, we synthesized prostate cancer-targeting poly(lactide-co-glycolic acid) (PLGA) nanobubbles (NBs) modified using A10-3.2 aptamers targeted to prostate-specific membrane antigen (PSMA) and encapsulated paclitaxel (PTX). We also investigated their impact on ultrasound (US) imaging and therapy of prostate cancer. PTX-A10-3.2-PLGA NBs were developed using water-in-oil-in-water (water/oil/water) double emulsion and carbodiimide chemistry approaches. Fluorescence imaging together with flow cytometry verified that the PTX-A10-3.2-PLGA NBs were successfully fabricated and could specifically bond to PSMA-positive LNCaP cells. We speculated that, in vivo, the PTX-A10-3.2-PLGA NBs would travel for a long time, efficiently aim at prostate cancer cells, and sustainably release the loaded PTX due to the improved permeability together with the retention impact and US-triggered drug delivery. The results demonstrated that the combination of PTX-A10-3.2-PLGA NBs with low-frequency US achieved high drug release, a low 50% inhibition concentration, and significant cell apoptosis in vitro. For mouse prostate tumor xenografts, the use of PTX-A10-3.2-PLGA NBs along with low-frequency US achieved the highest tumor inhibition rate, prolonging the survival of tumor-bearing nude mice without obvious systemic toxicity. Moreover, LNCaP xenografts in mice were utilized to observe modifications in the parameters of PTX-A10-3.2-PLGA and PTX-PLGA NBs in the contrast mode and the allocation of fluorescence-labeled PTX-A10-3.2-PLGA and PTX-PLGA NBs in live small animals and laser confocal scanning microscopy fluorescence imaging. These results demonstrated that PTX-A10-3.2-PLGA NBs showed high gray-scale intensity and aggregation ability and showed a notable signal intensity in contrast mode as well as aggregation ability in fluorescence imaging. In conclusion, we successfully developed an A10-3.2 aptamer and loaded PTX-PLGA multifunctional theranostic agent for the purpose of obtaining US images of prostate cancer and providing low-frequency US-triggered therapy of prostate cancer that was likely to constitute a strategy for both prostate cancer imaging and chemotherapy. Keywords: nanobubbles, ultrasound imaging, paclitaxel, cancer therapy, aptamer, prostate-specific membrane antigenWu MWang YWang YRZhang MBLuo YKTang JWang ZGWang DHao LWang ZBDove Medical Pressarticlenanobubblesultrasound imagingpaclitaxelcancer therapyaptamerprostate-specific membrane antigenMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 5313-5330 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanobubbles ultrasound imaging paclitaxel cancer therapy aptamer prostate-specific membrane antigen Medicine (General) R5-920
spellingShingle	nanobubbles ultrasound imaging paclitaxel cancer therapy aptamer prostate-specific membrane antigen Medicine (General) R5-920 Wu M Wang Y Wang YR Zhang MB Luo YK Tang J Wang ZG Wang D Hao L Wang ZB Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
description	Meng Wu,1,2 Ying Wang,3 Yiru Wang,2 Mingbo Zhang,2 Yukun Luo,2 Jie Tang,2 Zhigang Wang,4 Dong Wang,5 Lan Hao,4 Zhibiao Wang6 1School of Medicine, Nankai University, Tianjin, 2Department of Ultrasound, Chinese PLA General Hospital, Beijing, 3Wuhan Textile University, Wuhan, 4Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital of Chongqing Medical University, 5Department of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, 6College of Biomedical Engineering, Chongqing Medical University, Chongqing, People’s Republic of China Abstract: In the current study, we synthesized prostate cancer-targeting poly(lactide-co-glycolic acid) (PLGA) nanobubbles (NBs) modified using A10-3.2 aptamers targeted to prostate-specific membrane antigen (PSMA) and encapsulated paclitaxel (PTX). We also investigated their impact on ultrasound (US) imaging and therapy of prostate cancer. PTX-A10-3.2-PLGA NBs were developed using water-in-oil-in-water (water/oil/water) double emulsion and carbodiimide chemistry approaches. Fluorescence imaging together with flow cytometry verified that the PTX-A10-3.2-PLGA NBs were successfully fabricated and could specifically bond to PSMA-positive LNCaP cells. We speculated that, in vivo, the PTX-A10-3.2-PLGA NBs would travel for a long time, efficiently aim at prostate cancer cells, and sustainably release the loaded PTX due to the improved permeability together with the retention impact and US-triggered drug delivery. The results demonstrated that the combination of PTX-A10-3.2-PLGA NBs with low-frequency US achieved high drug release, a low 50% inhibition concentration, and significant cell apoptosis in vitro. For mouse prostate tumor xenografts, the use of PTX-A10-3.2-PLGA NBs along with low-frequency US achieved the highest tumor inhibition rate, prolonging the survival of tumor-bearing nude mice without obvious systemic toxicity. Moreover, LNCaP xenografts in mice were utilized to observe modifications in the parameters of PTX-A10-3.2-PLGA and PTX-PLGA NBs in the contrast mode and the allocation of fluorescence-labeled PTX-A10-3.2-PLGA and PTX-PLGA NBs in live small animals and laser confocal scanning microscopy fluorescence imaging. These results demonstrated that PTX-A10-3.2-PLGA NBs showed high gray-scale intensity and aggregation ability and showed a notable signal intensity in contrast mode as well as aggregation ability in fluorescence imaging. In conclusion, we successfully developed an A10-3.2 aptamer and loaded PTX-PLGA multifunctional theranostic agent for the purpose of obtaining US images of prostate cancer and providing low-frequency US-triggered therapy of prostate cancer that was likely to constitute a strategy for both prostate cancer imaging and chemotherapy. Keywords: nanobubbles, ultrasound imaging, paclitaxel, cancer therapy, aptamer, prostate-specific membrane antigen
format	article
author	Wu M Wang Y Wang YR Zhang MB Luo YK Tang J Wang ZG Wang D Hao L Wang ZB
author_facet	Wu M Wang Y Wang YR Zhang MB Luo YK Tang J Wang ZG Wang D Hao L Wang ZB
author_sort	Wu M
title	Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
title_short	Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
title_full	Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
title_fullStr	Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
title_full_unstemmed	Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
title_sort	paclitaxel-loaded and a10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/4434a01d73bb415e941cf48af19d7af0
work_keys_str_mv	AT wum paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT wangy paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT wangyr paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT zhangmb paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT luoyk paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT tangj paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT wangzg paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT wangd paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT haol paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer AT wangzb paclitaxelloadedanda1032aptamertargetedpolylactidecoglycolicacidnanobubblesforultrasoundimagingandtherapyofprostatecancer
_version_	1718401364012302336

Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer

Ejemplares similares